Diabetes can be treated effectively by the nanoparticles (NPs), which have been converted into nanomedicine. The present study describes the synthesis of Zinc oxide nanoparticles (ZnO NPs) using Bambusa arundinacea (BA), their antidiabetic, antibacterial, and anticancer potential. Histopathological studies of synthesized ZnO NPs and BA extract were carried out on male Wistar rats. The Wistar rats were divided into normal, toxicant, standard, and test groups. It is observed that the ZnO NPs have shown enhanced anti-diabetic potential when compared with BA extract. It is mainly due to the extensive pharmacological and biological properties of ZnO NPs. Further experiments needed to be carried out to confirm the exact mechanism of ZnO NPs for anti-hyperglycemic activity. Good antibacterial efficacy of biosynthesized ZnO NPs against gram-positive organisms was observed. The zone of inhibition values of 14, 16, 17, 18 mm for Staphylococcus aureus (S.aureus) and 12, 14, 15, 17 mm for Bacillus subtilis (B. Substilis) were observed for the concentration of 25, 50, 100, 150 µl. Further, ZnO NPs also exhibited anticancer activity against MCF-7 cell lines. These results indicate that bio-synthesized ZnO NPs have prospective pharmaceutical applications.

可以通过已被转化为纳米药物的纳米颗粒（NPs）有效治疗糖尿病。本研究描述了使用棍棒竹（Bambusa arundinacea（BA））合成氧化锌纳米颗粒（ZnO NPs ），它们具有抗糖尿病，抗菌和抗癌的潜力。在雄性Wistar大鼠上进行了合成的ZnO NP和BA提取物的组织病理学研究。Wistar大鼠分为正常，有毒，标准和测试组。观察到与BA提取物相比，ZnO NPs具有增强的抗糖尿病潜力。这主要是由于ZnO NP具有广泛的药理和生物学特性。需要进行进一步的实验以确认ZnO NPs的抗高血糖活性的确切机制。观察到生物合成的ZnO NP对革兰氏阳性生物具有良好的抗菌作用。金黄色葡萄球菌（S.aureus）的抑制值为14、16、17、18 mm，枯草芽孢杆菌（B. Substilis）的抑制值为12、14、15、17 mm观察到25、50、100、150μl的浓度。此外，ZnO NPs还表现出对MCF-7细胞系的抗癌活性。这些结果表明生物合成的ZnO NP具有潜在的药物应用。